Background Significant progress has been made in the treatment of selected malignancies
with immune-modulating antibodies. Phase III trials of anti-CTLA-4 in melanoma and anti-PD …

中国肺癌脑转移诊治专家共识（2017年版） - PMC Back to Top Skip to main content NIH NLM Logo
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Preview …

Five-year survival rates have not increased appreciably for patients with primary and
metastatic brain tumors. Nearly 17,000 patients die from primary brain tumors, whereas …

石 远凯 (Yuankai SHI), 1,* 孙 燕 (Yan SUN), 1 于 金明 (Jinming YU), 2 丁 翠敏 (Cuimin
DING), 3 马 智勇 (Zhiyong MA), 4 王 子平 (Ziping WANG), 5 王 东 (Dong WANG), 6 王 征 …

Objective: This retrospective study investigated the efficacy and safety of bevacizumab
treatment for refractory brain edema. Methods: Between March 2009 and December 2015 …

This study evaluates the efficacy and safety of bevacizumab (BEV) in the treatment of non-
small cell lung cancer (NSCLC) patients with brain metastases (BM) by performing meta …

The aim of this study was to explore prognostic factors for non-small cell lung cancer
(NSCLC) patients with brain metastases (BM) on the basis of EGFR mutation status. Among …

Central nervous system (CNS) metastases are common in patients with advanced non-small
cell lung cancer (NSCLC), occurring in 24% to 44% of patients in the course of their disease …

Lung cancer is the leading cause of cancer-related deaths worldwide. The most common
pathological type of lung cancer is non-small cell lung cancer (NSCLC). The incidence of …

Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in
China, exerts antiangiogenic and antineoplastic function through selectively binding and …